Efficacy and tolerance of the newly developed cephalosporin cefquinome in bacterial respiratory diseases of pigs

The efficacy of the recently developed cephalosporin preparation cefquinome in the treatment of bacterial respiratory diseases in store pigs, dosage 2 mg/kg BW on three or five consecutive days, was compared to the effectiveness of amoxicillin (7.5 mg/kg BW) and enrofloxacin (2.5 mg/kg BW) in a controlled, randomised field trial. Cefquinome showed superior therapeutic results (p <0.05) to amoxicillin and enrofloxacin, referring to sustained cure rates and weight gain. The outstanding sustained cure rates of 90.5% (amoxicillin 80.3% and enrofloxacin 83.1%), the low relapse rates and the excellent tolerability make cefquinome a very good drug in the therapy of bacterial respiratory diseases in pigs, in a daily dosage of 2.0 mg/kg BW on three consecutive days.